The price of Viking Therapeutics Inc (NASDAQ:VKTX) shares last traded on Wall Street rose 15.12% to $17.36.
Based on available information, 11 analysts follow Viking Therapeutics Inc (NASDAQ:VKTX). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $40.00 and a low of $28.00, we find $34.00. Given the previous closing price of $15.08, this indicates a potential upside of 125.46 percent. VKTX stock price is now 58.78% away from the 50-day moving average and 14.36% away from the 200-day moving average. The market capitalization of the company currently stands at $1.74B.
Among analysts, 0 rate the stock a hold while 10 rate it a buy. Brokers who have rated the stock have averaged $33.80 as their price target over the next twelve months.
In other news, Rowland Charles A Jr, Director sold 40,000 shares of the company’s stock on May 16. The stock was sold for $1,000,000 at an average price of $25.00. Upon completion of the transaction, the Director now directly owns 30,000 shares in the company, valued at $0.52 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 16, Director MACARTNEY LAWSON sold 16,000 shares of the business’s stock. A total of $384,000 was realized by selling the stock at an average price of $24.00. This leaves the insider owning 47,965 shares of the company worth $0.83 million. Insiders disposed of 1,764,159 shares of company stock worth roughly $30.63 million over the past 1 year. A total of 10.64% of the company’s stock is owned by insiders.
A candlestick chart of Viking Therapeutics Inc (NASDAQ: VKTX) showed a price of $15.05 on Tuesday morning. During the past 12 months, Viking Therapeutics Inc has had a low of $3.54 and a high of $25.72. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 28.44, and a quick ratio of 28.44. The fifty day moving average price for VKTX is $10.93 and a two-hundred day moving average price translates $15.18 for the stock.
The latest earnings results from Viking Therapeutics Inc (NASDAQ: VKTX) was released for Sep, 2023.
Viking Therapeutics Inc(VKTX) Company Profile
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
